SOHO 2022 Tenth Annual Meeting

 

SOHO 2022 Tenth Annual Meeting
M

SOHO 2022: The Emerging Potential of Bispecific Antibodies as Monotherapy and in Combination for Aggressive B-Cell Lymphoma

By SOHO 2022 Tenth Annual Meeting FEATURING Michael Dickinson
By SOHO 2022 Tenth Annual Meeting FEATURING Michael Dickinson
102 views
October 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Lymphoma
10:00
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Biology and Treatment of LGL Leukemia

Feat. T. Loughran
10:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Hodgkin Lymphoma

Feat. N. Bartlett
10:19
SOHO 2022 Tenth Annual Meeting

Next Questions: Mantle Cell Lymphoma

Feat. K. Maddocks
11:27
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: T-Cell Lymphoma

Feat. S. Iyer
12:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Follicular Lymphoma

Feat. G. Salles
15:31
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What's Next in Aggressive B-Cell Lymphoma?

Feat. L. Sehn
10:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: Cellular Therapy

Feat. K. Komanduri
16:19
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: CAR T-Cell vs. AUTO HCT for R/R DLBCL - Pro AUTO H…

Feat. C. Sauter
12:05
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: CAR T-Cell vs. AUTO HCT for R/R DLBCL - Pro CAR T-…

Feat. M. Kamdar
08:34
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Camidanlumab Tesirine - Updated Efficacy and Safety in Pa…

Feat. A. Herrera
16:42
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Treating Hodgkin Lymphoma After Brentuximab Vedotin and A…

Feat. A. Herrera
16:18
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Sequencing Novel Agents in Frontline and Second-Line Trea…

Feat. A. Moskowitz
07:04
SOHO 2022 Tenth Annual Meeting

Phase 1/2 BRUIN Study - Updated Results on Pirtobrutinib in Previous…

Feat. J. Cohen
19:47
SOHO 2022 Tenth Annual Meeting

Emerging Treatment Options for MCL

Feat. J. Ruan
13:18
SOHO 2022 Tenth Annual Meeting

Immunotherapeutic Options for Patients With MCL Who Progress on BTK …

Feat. J. Cohen
14:31
Tycel Phillips

The Role of Targeted Therapies in Frontline Treatment of MCL

16:52
SOHO 2022 Tenth Annual Meeting

Is it Time to Recognize the Biological Heterogeneity of MCL?

Feat. A. Goy
08:47
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Cost-Effectiveness of Polatuzumab Vedotin in Previously U…

Feat. J. Burke
08:56
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Results from POLARIX, a Phase III Study of Pola-R-CHP vs.…

Feat. C. Flowers
13:55
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Managing the Elderly Patient With Aggressive B-cell Lymph…

Feat. C. Thieblemont
11:32
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CNS Prophylaxis in DLBCL

Feat. V. Orellana-Noia
14:57
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Treatment of Aggressive B-cell Lymphoma Post-CAR T-Cell T…

Feat. G. Nowakowski
15:19
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Emerging Potential of Bispecific Antibodies as Monoth…

Feat. M. Dickinson
15:03
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Choosing CAR T-Cell Therapy vs. ASCT in R/R Aggressive B-…

Feat. M. Kamdar
15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg
05:56
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Pivotal Results From a Phase I/II Study of Mosunetuzumab …

Feat. L. Nastoupil
19:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Using Biology to Determine Type and Duration of Treatment…

Feat. P. Kapoor
15:04
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Future Role of Bispecific Antibodies in the Treatment of …

Feat. E. Budde
15:37
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What Is the Role of Transplantation for FL in the Era of …

Feat. M. Hamadani
15:08
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Sequencing Therapy in Indolent Lymphoma - Treatment Choic…

Feat. L. Nastoupil
10:04
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Correlation of TRBC1 by Flow Cytometry With Molecular T-C…

Feat. T. Dexter
14:13
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Advances in the Treatment of NK/T Cell Lymphoma

Feat. W. Kim
16:35
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Integrating Novel Agents Into the Management of Cutaneous…

Feat. P. Allen
15:40
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Novel Treatment Approaches in Relapsed/Refractory PTCL

Feat. M. Lunning
15:49
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Next Rational Therapeutic Regimen in Newly Diagnosed …

Feat. N. Mehta-Shah
14:21
SOHO 2022 Tenth Annual Meeting

SOHO 2022: From Bench to Bedside - A Translational Scientist's …

Feat. F. Vega
21:46
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CAR T-Cells in Indolent B-Cell Lymphomas

Feat. J. Abramson
18:24
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Challenging Cases in Rare T-Cell Lymphomas

Feat. S. Barta
11:16
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Basis for Targeting the Microenvironment in Hodgkin Lymph…

Feat. C. Steidl
11:27
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CAR T-Cell Therapy in Hodgkin Lymphoma

Feat. C. Ramos
13:22
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Next Generation of Novel Agents in Development for Ag…

Feat. J. Westin